Clinical Trials Directory

Trials / Unknown

UnknownNCT03796611

Phenotypic and Functional Study of 4BL B Cells in Multiple Sclerosis (MS)

Status
Unknown
Phase
Study type
Observational
Enrollment
172 (estimated)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Recent works highlight the B cells involvement in multiple sclerosis (MS) pathology but their role remains poorly understood. It was previously described that activated memory B cells called 4BL due to the increased expression of 4-1BBL, an activation marker, induce pro-inflammatory response by activating T CD8+ lymphocytes. Those 4BL cells are also described in systemic inflammation in 80 years old people explaining the poor efficiency of vaccination in that sub population. Those 4BL cells can also induce anti-tumoral T cell response. The hypothesize is that 4BL may induce a pathogenic inflammatory response in MS.

Detailed description

the aim to compare the proportion of peripheral (blood) 4 BL cells but also 4-BL cells in cerebro spinal fluid (CSF) in MS compared to healthy controls and to other inflammatory neurological disease but also non inflammatory neurological disease. For all groups of patients and controls it will collect blood and CSF only once (at diagnosis time for patients). Blood collect from healthy controls will come from transfusion volunteers and we won't have CSF from them. For patients from the MS group, the blood collect will be sequential at diagnosis, 3, 6, 12 and 24 months after during the follow up. In the blood and CSF we will evaluate: * percentage of 4 BL cells. 4 BL cells are found using cytometric parameters * capacity of 4 BL cells to induce inflammatory response in vitro: percentage of induced activated TCD8 proliferation after cell culture using extracellular and intracellular cytometric parameters

Conditions

Timeline

Start date
2020-12-01
Primary completion
2022-10-01
Completion
2022-10-01
First posted
2019-01-08
Last updated
2020-09-16

Source: ClinicalTrials.gov record NCT03796611. Inclusion in this directory is not an endorsement.